Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky; Robley Rex Veterans Affairs Medical Center, Louisville, Kentucky.
Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky.
Transl Res. 2018 Nov;201:26-39. doi: 10.1016/j.trsl.2018.08.002. Epub 2018 Aug 10.
Patients with systemic lupus erythematosus frequently develop lupus nephritis (LN), a condition that can lead to end-stage kidney disease. Multiple serum and urine biomarkers for LN have been proposed in recent years, yet none have become incorporated into clinical use. The majority of studies have been single center with significant variability in cohorts, assays, and sample storage, leading to inconclusive results. It has become clear that no single biomarker is likely to be sufficient to diagnose LN, identify flares, and define the response to therapy and prognosis. A more likely scenario is a panel of urine, serum, tissue, and genetic biomarkers. In this review, we summarize traditional and novel biomarkers and discuss how they may be utilized in order to bring precision medicine to clinical practice in LN.
系统性红斑狼疮患者常发生狼疮肾炎(LN),这可导致终末期肾病。近年来提出了多种用于 LN 的血清和尿液生物标志物,但均未纳入临床应用。大多数研究为单中心研究,队列、检测和样本储存存在显著差异,导致结果不确定。很明显,可能没有单一的生物标志物足以诊断 LN、识别疾病活动、确定对治疗的反应和预测预后。更有可能的是一组尿液、血清、组织和遗传生物标志物。在这篇综述中,我们总结了传统和新型生物标志物,并讨论了如何利用它们将精准医学应用于 LN 的临床实践。